Gcap14 Inhibitors
Gcap14 inhibitors encompass a diverse range of chemical compounds designed to specifically target and impede the function of the Gcap14 protein, a regulatory component implicated in cellular signaling pathways. These inhibitors operate by engaging with the molecular mechanisms that Gcap14 influences, effecting a decrease in its regulatory activity. The inhibition process is highly nuanced and involves either direct binding to the Gcap14 protein, which disrupts its ability to interact with other cellular components, or indirect interference with the signaling cascades that Gcap14 modulates. The direct inhibitors of Gcap14 tightly bind to active sites or allosteric sites on the protein, thereby preventing its interaction with downstream signaling molecules. This blockade is essential for impeding the progression of the signaling events that Gcap14 typically regulates. By contrast, indirect inhibitors might not interact with Gcap14 itself but rather target upstream regulators or parallel pathways that are crucial for Gcap14's activation or its subsequent action. These compounds may alter the phosphorylation status of Gcap14 or modify the cellular concentrations of secondary messengers that are vital for Gcap14's function.
The specificity of Gcap14 inhibitors is a key aspect of their design, ensuring that they elicit a targeted effect on the protein without broadly affecting other cellular proteins or pathways. This specificity derives from the chemical structure of the inhibitors, which is tailored to the unique features of Gcap14 or its associated signaling components. Some inhibitors might mimic the natural substrates or ligands of Gcap14, competitively inhibiting their binding and thus inactivating the protein's function. Others might bind irreversibly to the protein, leading to a sustained suppression of its activity. The indirect inhibitors, meanwhile, might work by modulating the activity of kinases or phosphatases that are responsible for the post-translational modification of Gcap14, thereby influencing its activity state. Both types of inhibitors are crucial for elucidating the biological role of Gcap14 and for understanding how its dysregulation can affect cellular functions. Through these mechanisms, Gcap14 inhibitors serve as valuable tools in the study of cellular signaling, allowing researchers to dissect the complex networks in which Gcap14 operates and to further understand the protein's role in maintaining cellular homeostasis.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is a selective inhibitor of mitogen-activated protein kinase kinase (MEK), which indirectly affects the Gcap14 protein by reducing the activity of the MAPK/ERK pathway that Gcap14 could be associated with, leading to decreased Gcap14 function due to the reduced phosphorylation events that are essential for its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are upstream regulators of the AKT signaling pathway. Inhibition of this pathway can reduce the phosphorylation and activation of downstream components that may be crucial for Gcap14's role in cellular processes, indirectly causing a decrease in Gcap14 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR (mammalian target of rapamycin), which plays a key role in protein synthesis and cell growth. Inhibition of mTOR can downregulate processes that are potentially vital for Gcap14's function, thereby reducing its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK, a kinase involved in inflammatory responses and stress-induced signaling. Inhibition of p38 MAPK may alter cellular responses that Gcap14 is involved in, leading to its functional inhibition. | ||||||
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC 23766 inhibits Rac1 activation by preventing its interaction with specific guanine nucleotide exchange factors (GEFs). As Rac1 is involved in actin cytoskeleton reorganization and cell motility, inhibition of Rac1 might affect processes that Gcap14 regulates, thereby inhibiting Gcap14 activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor that can affect protein degradation pathways. By inhibiting proteasome-mediated degradation, MG132 could influence the turnover of proteins that modulate Gcap14's pathway, indirectly reducing Gcap14's activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which can affect transcription factor activation and cellular stress responses. JNK inhibition could decrease the activity of proteins that regulate Gcap14's function, leading to diminished Gcap14 activity. | ||||||
BAPTA/AM | 126150-97-8 | sc-202488 sc-202488A | 25 mg 100 mg | $138.00 $458.00 | 61 | |
BAPTA-AM is a cell-permeable calcium chelator that can reduce intracellular calcium levels, potentially impacting calcium-dependent signaling pathways that Gcap14 may be involved in, leading to its functional inhibition. | ||||||
WZ8040 | 1214265-57-2 | sc-364656 sc-364656A | 5 mg 10 mg | $255.00 $480.00 | ||
WZ4003 is a selective inhibitor of NUAK family kinase (NUAK1), which is involved in cellular stress responses and metabolism. Inhibition of NUAK1 could affect pathways that regulate Gcap14 activity, thereby reducing its function. | ||||||
XAV939 | 284028-89-3 | sc-296704 sc-296704A sc-296704B | 1 mg 5 mg 50 mg | $36.00 $117.00 $525.00 | 26 | |
XAV939 is a tankyrase inhibitor which leads to stabilization of axin and inhibition of the Wnt/β-catenin signaling pathway. Although Gcap14 is not directly involved in this pathway, downstream effects of Wnt signaling inhibition could lead to reduced Gcap14 activity due to altered cellular contexts. | ||||||